We invest our human capital—our capabilities, databases, people, and tools—in promising biotech companies to help them scale and achieve high ambitions, using our proven Leap by McKinsey methodology.

2021年4月30日 · In an effort to understand worldwide biotech financing in the context of the COVID-19 crisis, McKinsey analyzed the sector’s financial performance and interviewed 20 C-level executives from small and midsize biotechs and venture-capital (VC) firms.

2023年12月12日 · Trends in biotechnology in 2022 and 2023 indicate that innovative platforms continue to spur VC investment. We look at current trends and what’s ahead.

2024年2月29日 · Acquiring precommercial biotech assets to fuel growth renewed deal success for pharmaceutical companies, and proactively shaping the business portfolio to improve profitability provided the key for medical technology companies. This year promises considerable deal activity across the sector.

2022年6月10日 · McKinsey research shows from 2019 to 2021, VCs plowed $35 billion into biotechs with advanced platform technologies that could transform the industry

2021年1月29日 · Over the past five years, however, an innovative business model has emerged for biotech. In it, a portfolio manager controls a set of companies spanning multiple technologies and disease areas.

2025年1月10日 · Browse our collection of articles for an in-depth look at the opportunities, challenges, and implications for stakeholders in this fast-evolving field, and explore how McKinsey’s new Digital Capability Center for Cell and Gene Therapy will help biopharma companies accelerate digital transformations in manufacturing and the journey to ...

2020年5月13日 · Advances in biological science could transform economies and societies, helping to tackle global challenges from climate change to pandemics. A confluence of advances in biological science and accelerating development of computing, automation, and artificial intelligence is fueling a new wave of innovation.

Helping biotech companies across the entire value chain, from early-stage companies getting initial funding to established companies launching into international markets.

2025年1月29日 · Our analysis 2 Our molecule-model-based approach establishes a novel value pool analysis of the pharma supply chain services at the level of the individual drug, using proprietary industry benchmarks (for example, McKinsey’s Pharmaceutical Operations Benchmarking and Opportunity Sizing [POBOS]) and industry perspectives on outsourcing ...

2025年1月28日 · Gen AI has become a hot topic among leaders at most big companies, more than two-thirds of which intend to increase their investments in the technology over the next three years. 1 “Generative AI in the pharmaceutical industry: Moving from hype to reality,” McKinsey, January 9, 2024; “The state of AI in 2023: Generative AI’s breakout year,” QuantumBlack, AI …

2021年8月19日 · McKinsey’s Biotech Innovation Index assesses innovation and funding in terms of four indicators: discovery (measured in numbers of patents and publications); translation (measured in numbers of new biotech companies and average amounts raised in early-stage financing); growth capital (measured in average amounts raised during late-stage ...

2025年1月9日 · In this challenging environment, pharma leaders are turning to advanced technologies such as digital and analytics (DnA) solutions to reshape R&D operations and deliver new efficiencies, such as faster discovery of new molecular entities and …

2024年11月25日 · Within the pharmaceutical industry, first-time launchers play a critical role as innovators. They are developing breakthroughs in new modalities that may revolutionize care for patients with limited treatment options.

2025年1月9日 · To reduce the complexities associated with research and early development, leading pharmaceutical companies are implementing leaner processes and utilizing technological advances in automation and digitization. Some of these have already led to a 40 percent reduction in cycle time from concept to first-in-human (FIH) trials.

2025年1月9日 · ,” McKinsey, May 13, 2021. Similarly, biotechnology company Flagship Pioneering employs rigorous criteria to enable rapid resource reallocation. The company creates small teams working on one dedicated project with a budget of $1 million to $2 million. If proof of concept isn't achieved within six to 12 months, the team is disbanded.

2025年1月10日 · In late summer 2024, we surveyed more than 100 pharma and medtech leaders responsible for driving their organizations’ gen AI efforts. All respondents report having experimented with gen AI, and 32 percent say they have taken steps to scale the technology.

2025年1月9日 · Among top biopharmas, the number of unique assets in the clinical pipeline increased by an average of 15 to 30 percent between 2018 and 2024, 2 “Evaluate releases 2030 forecasts for global pharmaceutical market,” Evaluate Pharma, July 10, 2024; company websites. indicating leading players were moving to grow their portfolios and total ...

2025年1月10日 · CEOs in pharma, biotech, and medtech are increasingly building patient-centric businesses but are struggling to do so. Avoiding five common roadblocks can help leaders build successful businesses. ... Jake Henry, and Pepe Campello Gomis, with Franca Ziervogel, representing views from McKinsey’s Life Sciences Practice and Leap by McKinsey.

2024年7月31日 · Rapid advancements in science and technology are challenging pharma and biotech companies’ approaches to talent. What R&D skills do they need today, and how can they sustain this workforce?